Expanded analysis of vertebral endplate disruption and its impact on vertebral compression fracture risk

Radiation Oncology

Table 2 Cumulative incidence of vertebral compression fracture

Variable	Number (173)	1-year cumulative incidence of VCF	P value
Age
≥60	101	16%
<60	72	17%	0.65
Sex
Male	102	14%
Female	71	18%	0.12
Primary cancer
NSCLC/Breast/ano-colorectal	51	25%
Others	122	10%	< 0.001
BMI
<25	59	18%
25-29.9	53	10%
≥30	61	10%	0.33
Steroid use
Yes	18	38%
No	155	13%	0.01
Antiresorptive medicine
Yes	59	16%
No	114	15%	0.77
Osteoporosis
Yes	10	0%
No	163	17%	0.83
Fractionation
Single	22	20%
Multiple	151	14%	0.90
Radiotherapy dose
BED10 < 51.3 Gy	63	20%
BED10 ≥ 51.3 Gy	110	10%	0.35
D80%<27 Gy	56	14%
D80 ≥ 27 Gy	117	15%	0.45
D50%<28 Gy	77	10%
D50%≥28 Gy	96	20%	0.14
Bilsky
0	126	10%
1	47	28%	< 0.001
SINS score
≥7	75	32%
<7	98	4%	< 0.001
EP disruption
Yes	69	30%
No	104	5%	< 0.001

abbreviations: BMI: body mass index; BED10: biologically effective dose alpha/beta 10; PTV: planning target volume; EP: endplate; NSCLC: Non-Small Cell Lung Cancer; SINS: spine instability neoplastic score; VCF: vertebral compression fracture

ISSN: 1748-717X